Navigation Links
Somanetics Announces New FDA 510(K) Clearance
Date:4/16/2009

- Labeling expanded to include improved patient outcomes and

real-time measurement accuracy -

TROY, Mich., April 16 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) announced today a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the labeling for its INVOS(R) Cerebral/Somatic Oximeter. The new labeling allows a claim of improved patient outcomes after surgery when the INVOS System is used to manage therapies in patients above 2.5 kilograms (kg) at risk for reduced or absent blood flow. Additionally, its indications for use now reflect the INVOS System's ability to generate accurate real-time measurements of blood oxygen saturation in this same patient population, in addition to its previous clearance as a trend monitor in any individual.

These changes make the INVOS System the only commercially-available cerebral/somatic oximeter backed by an improved patient outcomes claim, and the only cerebral/somatic system cleared for use on neonates less than 2.5 kg.

The INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter noninvasively monitors site-specific blood oxygen levels to help surgical and critical care teams protect their patients against brain and vital organ area damage, or even death.

"The clinical data we submitted and subsequent 510(k) clearance demonstrate that improved patient outcomes are possible with the use of our INVOS System, and that our device can benefit cardiac surgery patients as well as high-risk general surgery patients, such as the elderly undergoing major abdominal surgery," explains Bruce Barrett, Somanetics' president and CEO.

Marc S. Kanchuger, MD, Associate Professor and Chief of Cardiothoracic Surgery and Transplant Anesthesia at NYU Medical Center adds, "I'm not surprised by the FDA's decision. We use the INVOS System routinely in all our cardiac surgeries in an effort to protect patients from ischemic brain complications. I suspect today's news will spark further adoption of the technology by the medical community."

Barrett continues, "Our expanded indication reinforces the device's applicability for on-label treatment of patients at any weight. For patients above 2.5 kilograms, including adults, children and most infants, our proprietary algorithm generates accurate, real-time measurements for immediate use by the care team. In patients below 2.5 kilograms, which is extremely common in our neonatal market, clinicians may use our device on-label as a trend monitor."

The labeling also removed "not demonstrated in disease states" from the indication for patients weighing greater than 2.5 kg, and includes additional 510(k) language on these three points:

  • The measurement of regional cerebral oxygen saturation (rSO2) is an indication of whether oxygen delivery to the brain is adequate. Prolonged declines in rSO2 are indicative of, or may result in, potential brain injury.

  • When used as an indication of compromised cerebral oxygenation, interventions to return the patient's rSO2 to baseline using the INVOS System have been shown to improve outcomes after surgery.

  • In neonates, infants and children, cerebral and somatic rSO2 provide noninvasive indications of oxygen changes in the cerebral and peripheral circulatory systems and may provide an early indication of oxygen deficits associated with impending shock states and anaerobiosis.

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter which noninvasively provides accurate, real-time blood oxygen measurements in patients greater than 2.5 kilograms, and trend monitoring of this parameter for individuals of any weight. The INVOS System is the only commercially-available cerebral/somatic oximeter proven to improve outcomes in patients above 2.5 kilograms, and is the only cerebral/somatic oximeter system cleared for use on neonates less than 2.5 kg. Surgeons, anesthesiologists and other medical professionals can use data provided by the INVOS System, in conjunction with other available data, to identify oxygen imbalances in brain or other body tissue beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with an 11-year market track record, more than 600 clinical references and implementation at more than 700 U.S. hospitals. Somanetics also is developing a technology that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit www.somanetics.com.


'/>"/>
SOURCE Somanetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
2. Somanetics Corporation to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Somanetics Corporation to Release Fourth Quarter and Fiscal 2007 Financial Results and Host Conference Call January 23, 2008
4. Somanetics Corporation to Release First Quarter 2008 Financial Results and Host Conference Call March 18, 2008
5. Somanetics Reports Financial Results for the First Quarter of Fiscal 2008
6. Somanetics Announces Share Repurchase Program
7. Somanetics Announces Share Repurchase Program Increased by $15 Million
8. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
9. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
10. Somanetics Announces Share Repurchase Program Increased By $15 Million
11. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... San Ramon, CA (PRWEB) , ... February 23, 2017 , ... ... Kaplan, MD, FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and ... served as the chairman and CEO of the Virginia Mason Health System in Seattle ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... , ... February 22, 2017 , ... The Waismann ... the thousands of individuals who have recently fallen victim to America’s opioid epidemic. Now, ... Orange County, California, where they are free from the shame, stigma, and harmful ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National Nutrition ... addition, the Company is helping people live healthier ... customized prescription savings programs in all 50 states ... Assistance Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... Korea , Feb. 23, 2017 LG Innotek today ... LED for sterilization applications. As its sterilization performance is 1.5 times ... the short wavelength ultraviolet rays in the range of 200 -- 280nm, ... proliferation of bacteria by destroying their DNA. LG Innotek,s product emits ... ...
Breaking Medicine Technology: